SHMT2 and hepatocellular carcinoma: Moreover, SHMT2 has been reported to be up-regulated in a variety of cancers such as breast cancer, hepatocellular carcinoma, and lung cancer, and elevated expression of SHMT2 is significantly associated with poor prognosis of patients [15–17].